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Nanoemulsion Improves the Antifungal Activity of Allylic
Thiocyanates against Yeasts and Filamentous Pathogenic
Fungi
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Marilene H. Vainstein,[c] Letícia J. Danielli,[d] Vanessa Z. Bergamo,[a] Bruna Pippi,[a]
Miriam A. Apel,[d] Mário L. Teixeira,[e] Luis F. S. de Oliveira,[f] Michel M. Machado,[f]
Saulo F. de Andrade,[d] Marcus M. Sá,[g] Misael Ferreira,[g] Laiéli S. Munaretto,[g] Letícia Cruz,[b]
Gustavo P. Silveira,[h] Edilma Elayne,[h] and Alexandre M. Fuentefria[a]
We report the antifungal and antichemotactic activities of a
series of allylic thiocyanates with low toxicity. We also show
improved antifungal activity of the most promising compound
when used in a nanoemulsion (NE). The 4-chlorophenyl-
substituted allylic thiocyanate (compound 11) exhibited a
broad spectrum of antifungal activity and showed antichemo-
tactic effects with 100% reduction in leucocyte migration.
Minimal inhibitory concentrations ranged from 25 to 50 μg
mL  1, and the mechanism of action was related to complex-
ation with fungal ergosterol. The NE containing compound 11
enhanced the antifungal activity approximately 64-fold for
dermatophytes and 4-fold for Candida spp.. Compound 11 was
not mutagenic and did not cause cell death or significant
haemoloysis, although it exhibited mild dose-dependent DNA
damage. It was not an irritant for chorioallantoic membrane of
fertile white eggs and exhibited 100% inhibition of fungal
growth in an in vivo model of dermatophytosis. Our data
indicate that allylic thiocyanates are very promising for the
antifungal potential in nanostructured systems, with associated
anti-inflammatory effect.
Introduction
Fungal infections produce high rates of morbidity and mortal-
ity, especially in severely ill or immunocompromised pa-
tients.[1,2] Candida albicans is a prominent fungal pathogen in
humans. It is responsible for a wide spectrum of clinical
presentations, and infection that can lead to death.[3] In the last
20 years, C. albicans has been the most common strain isolated
from hospitalized patients. However, non–albicans Candida
(NAC) infections are rapidly growing. C. albicans, C. glabrata, C.
tropicalis and C. krusei account for 95–97% of all invasive fungal
infections caused by yeast of this genus.[4] In addition to yeast
infections, fungal infections caused by dermatophytes have
increased during the last decades.[5] These conditions also lead
to morbidity-associated cutaneous mycoses that are frequently
ineffectively treated.[6]
Illnesses caused by Candida spp. are associated with
inflammatory processes (also observed for dermatophytoses)[7,8]
that are possibly exacerbated by enzymes secreted by the
fungus during invasion.[9] Therefore, uncontrolled inflammation
can compromise treatment and lead to other associated
diseases.[10,11] Chemical compounds have been investigated for
their ability to inhibit leucocyte migration through an anti-
inflammatory mechanism (antichemotactic activity).[12] Thus, it
is interesting to investigate if new libraries of molecules exert
antifungal and anti-inflammatory effects.
Although numerous effective antifungal agents are avail-
able, their therapeutic outcome is less than optimal due to
limitations associated with toxicity and physicochemical char-
acteristics. Nanoparticles hold the promise to overcome these
problems due to their ability to improve bioavailability,
antifungal efficacy and aqueous solubility. Further, drug
incorporation into a nanoemulsion (NE) could greatly minimise
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its toxicity. Despite these potential advantages, there are few
marketed nanoparticle-based antifungal drug formulations, and
thus research into antifungal therapy with nanostructured
systems is needed.[13]
Allylic thiocyanates showed moderate-to-high activity
against methicillin-resistant Staphylococcus aureus (MRSA),[14]
Mycobacterium tuberculosis (Mtb),[15] human cancer cells[16] and
other targets.[17] Therefore, we present the antifungal activity of
functionalised allylic thiocyanates derived from the Morita-
Baylis-Hillman reaction,[18] as well as the toxicity and anti-
inflammatory properties of this collection of sulphur-containing
derivatives. The antifungal activity of the most promising
compound was also evaluated in NE and in an alternative
fungal infection model.
Results
Nanoemulsion
NE was prepared as a white and milky liquid with a macro-
scopically homogeneous appearance, bluish reflection and a
droplet size characteristic of colloidal systems. The pH of the
compound 11-containing NE (NE-C, 7.45 � 0.06) was slightly
higher compared to the placebo formulation (prepared without
the compound 11 - NE-WC, 7.29 � 0.09). Granulometric
analysis of the formulations revealed that the droplets were
190.42 � 8.64 nm for the NE composed of the active
compound 11 - NE-C and 225.3 � 29.67 nm for NE-WC.
Polydispersion index (PDI) values were 0.120 � 0.04 and 0.200
� 0.07 for NE-C and NE-WC, respectively.
The zeta potential (ZP) values were   8.68 � 0.31 mV and
  7.32 � 1.41 mV for NE-C and NE-WC, respectively. ZP
increased slightly for NE-C, which can be attributed to greater
physicochemical stability of the developed colloidal system. In
addition, the compound showed high values of total content
and encapsulation efficiency in the NE being 96% � 7.84 and
92%, respectively, which is attributed to the affinity of
compound 11 with the oil phase of the NE.
In vitro antifungal susceptibility tests
Eight fungal strains were initially used to evaluate the
antifungal activity of allylic thiocyanates 1–15 (Scheme 1;
Supporting Information, Table S1). Compounds 1, 4, 6, 7, 10,
12, 13 and 15 (Scheme 1) failed to inhibit fungal growth up to
the maximum evaluated concentration (50 μg mL  1). Com-
pounds 2, 3, 5, 8, 9 and 14 (Scheme 1) exhibited fungicide
activity against Candida spp., with minimal inhibitory concen-
trations (MICs) of 50 μg mL  1, but were not effective against
filamentous fungi. The compound 11 demonstrated a broad
fungistatic spectrum against dermatophytes and yeasts, with a
MIC of 50 μg mL  1 (Supporting Information, Table S1). It is
noteworthy that compound 11 inhibited the growth of drug-
resistant T. mentagrophytes, C. krusei, C. glabrata and C.
tropicalis (MICs and breakpoints of commercial antifungal
agents are presented in Supporting Information, Table S1).
Based on these findings, compound 11 was chosen for the
development of a NE.
The MICs of compound 11 in the free form and in a NE for
25 clinical strains of dermatophytes and Candida spp. are
presented in Table 1. For some species, such as T. rubrum, T.
schoenleinii, C. parapsilosis and others, thiocyanate 11 showed a
MIC of 25 μg mL  1. With the comparison of the MIC values that
inhibited approximately 50% of the clinical strains (MIC50) for
the free compound 11 and compound 11-containing NE
(NE  C) was possible to observe that NE  C was much more
active than the free compound (decrease of MIC values up to
64-fold for dermatophytes and 4-fold for Candida spp.). In
addition, NE  C was fungicidal at the MIC concentration for all
fungal species analysed. This is an important advantage, since
free compound 11 was only fungistatic. NE-WC showed no
antifungal activity; thus, the other components of the NE do
not exert antifungal activity.
In vivo antifungal efficacy in Infected Egg
Test-Chorioallantoic Membrane (IET-CAM)
For dermatophytes, infected CAM treated with compound 11
showed eggs without microbial growth in which the embryos
were still alive at the time of incubation (Supporting Informa-
tion, Table S2). We initially counted 1 x 102 – 1 x 103 conidia
mL  1. After the incubation period, the eggs treated with
compound 11 showed the absence of fungal growth (Support-
ing Information, Figure S1). Thus, compound 11 presented
100% efficiency in in vivo antifungal activity, considering that
the infection did not develop and no embryos died after
treatment with the compound. While untreated eggs scored
Scheme 1. Chemical structure of allylic thiocyanates 1–15.
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between 1 x 102 – 1 x 105 conidia mL  1 (measured in triplicate),
all eggs showed fungal growth, and all embryos died.
For the examined yeast strains (Supporting Information,
Table S2), fungal growth occurred on some embryos (1 x 104 –
1 x 105 colony forming units [CFU] mL  1) and consequently led
to death. For all clinical Candida strains analysed, only one out
of the 3 eggs showed fungal growth after treatment with
compound 11; this embryo subsequently died. Thus, com-
pound 11 was 66.6% effective in the yeast infection model
(Supporting Information, Table S2).
Embryonic death was evaluated both by egg translumines-
cence and embryo heartbeat cessation. After treatment with
compound 11 at a concentration 4 times higher than the MIC
(200 μg mL  1), we observed perfectly formed vessels just below
the chorioallantoic membrane (Supporting Information, Fig-
ure S1A), while these vessels were absent in untreated controls
(Supporting Information, Figure S1B). This finding suggested
overall disrupted embryonic development and consequent
non-viability.
Antichemotactic assay
Antichemotactic activity was expressed as a percentage of
neutrophil migration inhibition relative to controls. Compound
11, for all tested concentrations, significantly inhibited leuco-
cyte migration. Lipopolysaccharide from Escherichia coli (LPS;
Table 2) was used as chemoattractant. Complete leucocyte
migration inhibition occurred at the maximum evaluated
concentration (5 μg mL  1), while the positive control, indome-
thacin, inhibited approximately 60% of migration at the same
concentration. Compound 11 demonstrated the potential for
antichemotactic action because at a concentration 10 times
lower than the MIC it was able to inhibit leucocyte migration
completely.
Antifungal mechanism of action
Sorbitol assay
The MIC of compound 11 against Candida spp. and dermato-
phytes was evaluated in the presence and absence of sorbitol
at different times using anidulafungin (AND) as an antifungal
control (Supporting Information, Table S3). As expected, the
MIC of compound 11 increased after 48, 96 and 168 h due to
its fungistatic effect. However, the MICs were the same
regardless of being administrated with sorbitol. Meanwhile, the
minimal effective concentration (MEC) of AND changed
abruptly (more than 8 times) in the presence of sorbitol
(Supporting Information, Table S3).
Ergosterol assay
The MIC of compound 11 increased after addition of ergosterol
to all strains of Candida spp. and dermatophytes. For yeast (C.
albicans, C. tropicalis, C. krusei and C. glabrata), MICs increased
4–8-fold after addition of a total of 200 μg mL  1 (maximum
Table 1. MIC/MFCs (μg mL  1) of free compound 11 and nanoemulsion
containing compound 11 (NE-C).
Fungal strains Compound 11 NE-C
Dermatophytes (n=15)
Microsporum canis (MCA 01) 50/>50 1.56/1.56
Microsporum canis (MCA 33) 25/>25 0.78/0.78
Microsporum canis (MCA 38) 50/>50 0.78/0.78
Microsporum gypseum (MGY5 HCPA) 25/>25 1.56/1.56
Microsporum gypseum (MGY 42) 50/>50 1.56/1.56
Microsporum gypseum (MGY 50) 50/>50 1.56/1.56
Microsporum gypseum (MGY 58) 50/>50 1.56/1.56
Trichophyton mentagrophytes (TME 16*) 50/>50 0.78/0.78
Trichophyton mentagrophytes (TME 40) 25/>25 0.78/0.78
Trichophyton mentagrophytes (TME) 50/>50 1.56/1.56
Trichophyton rubrum (TRU 2 HCPA) 25/>25 0.78/0.78
Trichophyton rubrum (TRU 3 HCPA) 25/>25 0.78/0.78
Trichophyton rubrum (TRU 45) 50/>50 0.78/0.78
Trichophyton rubrum (TRU 48) 50/>50 1.56/1.56
Trichophyton schoenleinii (TSHO 3 HCPA) 25/>25 0.78/0.78
MIC50 50 0.78
MIC range 25 – 50 0.78 – 1.56
Yeasts (n=10)
Candida albicans (CA ATCC 18804) 50/>50 12.5/12.5
Candida albicans (CA 01) 25/>25 25/25
Candida krusei (CK 02) 50/>50 50/50
Candida krusei (CK 03) 25/>25 12.5/12.5
Candida glabrata (CG 05) 50/>50 50/50
Candida glabrata (CG 09) 50/>50 50/50
Candida tropicalis (CT ATCC 750) 25/>25 12.5/12.5
Candida tropicalis (CT 72 A*) 50/>50 50/50
Candida parapsilosis (CP 06) 50/>50 12.5/12.5
Candida parapsilosis (CP 07) 25/>25 12.5/12.5
MIC50 50 12.5
MIC range 25 – 50 12.5 – 50
*Multidrug-resistant and resistant fungal isolates; MIC, minimal inhibitory
concentration; MFC, minimal fungicidal concentration; MIC50, minimal
inhibitory concentration that inhibits approximately 50% of the clinical
strains analyzed; MIC range, minimum and maximum limits of MIC values;
n, number of clinical strains.
Table 2. In vitro effect of compound 11 and indomethacin compared to
negative control.
Samples Concentration (μg
mL  1)
Migration
(μm)
Migration
inhibition (%)
Compound
11
5 0.0 � 0.0 100.0*
1 16.0 � 2.8 78.0*
0.1 28.8 � 8.2 58.6*
0.01 51.2 � 8.0 26.2*
0.001 51.2 � 4.8 26.2*
Indomethacin
5 32.6 � 7.8 59.7*
1 34.0 � 5.7 57.9*
0.1 40.8 � 14.5 49.5*
0.01 95.6 � 7.7 0
Negative Con-
trol
- 80.8 � 8.4 0
Mean � standard deviation. *p < 0.05 indicates a significant difference
compared to negative control (reference chemoattractant - lipopolysac-
charide from Escherichia coli (LPS)) (ANOVA–Tukey’s test).
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concentration) of ergosterol during the 5 days of the experi-
ment (Supporting Information, Table S4). As expected, AmB
demonstrated an ergosterol-dependent effect. For instance,
after addition of 200 μg mL  1 of ergosterol, the MIC of
amphotericin B (AmB) against C. tropicalis increased from 0.5 to
>128 μg mL  1 (more than 256 times in this case; see Table S4).
The same trend was observed for the dermatophytes studied.
However, MICs increased more discretely in the case of
filamentous fungi (for example, 2-fold for compound 11; see
Table S4).
Scanning electron microscopy (SEM) analysis
C. albicans was treated with either the antifungal itraconazole
(ITZ) or the compound 11. Before addition of the drugs, C.
albicans cells appeared oval (as expected) without apparent
alteration (Figure 1A  B). After treatment with ITZ, changes in
cell shape and size were remarkable (Figure 1C  D; yellow
arrows point to damaged cells), and damage was also observed
from compound 11 treatment (Figure 1E  F; green arrows point
to damaged cells). For compound 11, the fungal cell appeared
to rupture, and it was possible to visualise extravasation of
intracellular material (Figure 1E; green arrows).
Figure 1. SEM images: (A and B) C. albicans ATCC 18804 without treatment (control); (C and D) treated with itraconazole and (E and F) treated with compound
11.
Full Papers
11666ChemistrySelect 2018, 3, 11663–11670 © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Mittwoch, 07.11.2018
1841 / 124012 [S. 11666/11670] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
Toxicity evaluation
Cytotoxicity, genotoxicity and mutagenicity assays
Compound 11 (50 μg mL  1) caused DNA damage similar to the
hydrogen peroxide (H2O2; 100 μM) control (Figure 2 - A).
However, at 25 μg mL  1, the cell damage was not significant
and was comparable to phosphate-buffered saline (PBS, neg-
ative control; Figure 2 - A). Approximately 70% and 90% of
leucocytes were viable after treatment with compound 11 at
50 and 25 μg mL  1, respectively (Figure 2 - B). Finally, micro-
nucleus was not observed after addition of 25-50 μg mL  1 of
compound 11 (Figure 2 - C).
Hemolysis
The mean percentage of haemoloysis (� SD) induced by
compound 11 at 50 μg mL  1 and 100 μg mL  1 (concentration 2
times higher than MIC) was 4.20% � 0.0028 and 4.35% �
0.0032, respectively. These values are considered very low
when compared to water, which causes 100% erythrocyte lysis.
PBS did not cause significant haemoloysis. These results
corroborated the aforementioned cytotoxicity evaluation in
human leucocytes.
Hen’s Egg Test-Chorioallantoic Membrane (HET-CAM)
The HET-CAM analysis showed the irritation score (IS) of 3.06 �
0.50 for the compound 11. This value classifies the compound
as a nonirritant, and suggests it is not allergenic to membranes
and thus suitable for future topical use.
Discussion
Previous data showed that compound 11 exhibited moderate-
to-good activity against C. albicans (12.5 μmol L  1) and C.
tropicalis (25 μmol L  1);[14] these findings corroborate to our
results. Furthermore, compounds 8, 9, 11 and 14 inhibited
MRSA growth,[14] and thus demonstrated a broad spectrum of
action against fungi and bacteria. Compound 11 and bromo-
substituted analogues 8 and 9 exhibited promising antituber-
cular activity against replicating and non-replicating forms of
Mtb H37Rv (MIC 0.25 μmol L
  1) with relatively low toxicity
toward VERO cells.[15] Contrarily, 2-chloro-substituted analogues
Figure 2. Effect of compound 11 (25 and 50 μg mL  1) in DNA damage (A), cell viability (B) and micronucleus frequency (C). a,b,cp <0.05 indicates significant
difference between the controls and the compound 11 (ANOVA followed by Tukey’s test).;
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10 and 12 were inactive against Mtb (MICs >128 μmol L  1).[15]
The same trend was observed in the current study for adducts
10 and 12, since both were not active at concentrations up to
50 μg mL  1 (Supporting Information, Table S1). Thus, com-
pound 11 is a potential antimicrobial agent that exhibits
broad-spectrum activity against MRSA, Candida spp., dermato-
phytes and Mtb. This profile was previously verified for
imidazolium salts, with chloro-derived compounds being the
most effective in vitro antifungal agents when compared to
other analogues.[19]
Lipophilicity at the 2- and 3-position of the aromatic ring
seems to play a pivotal role for activity (Scheme 1; Supporting
Information, Table S1). The best results in this sense were
achieved for compounds 8 and 14, both of which contained
more lipophilic groups, such as 2-bromophenyl and 2-naphthyl,
respectively. Other less lipophilic analogues, such as the 2-
nitro- and 2-chloro-compounds 1 and 10, were not active up to
50 μg mL  1. The presence of an electron-withdrawing sub-
stituent at the aryl group, including nitro (compounds 2 and 3),
bromo (compound 9) and chloro (compound 11), seemed to
improve activity. The only exception to this trend was the 4-
fluoro-substituted (compound 7) that was also inactive to the
endpoint chosen in this study. Meanwhile, thiocyanates
containing electron-donating groups, including methoxy (com-
pound 4) and methyl (compound 6), were not active up to 50
μg mL  1. Chain elongation was also deleterious to activity (see
the cinnamoyl derivative - compound 15; Supporting Informa-
tion, Table S1) as well as the simultaneous presence of two
substituents at the aromatic ring, such as in compounds 12
and 13. Hence, our screening of the thiocyanates 1–15 against
the present panel of fungi correlated with previous results for
these compounds towards Mtb[15] and bacteria,[14] allowed us to
select compound 11 as the best lead for further evaluation to
develop a new broad spectrum drug and NE to treat microbial
skin infections. Therefore, its mechanism of antifungal action,
anti-inflammatory capacity and toxicity were determined.
Our NE displayed all characteristics expected to a
nanostructure.[20–22] Droplet size and PDI may vary according to
the composition of the formulations and the method employed
in the preparation.[23] The presence of thiocyanate in the NE
reduced the droplet size and the PDI values, and these
observations indicate that this compound possess some surface
activity that contributes to the formation of smaller and
uniform droplets. Additionally, the NE-C showed a slightly
higher pH value attributed to the weakly basic character of the
thiocyano group. Incorporation of compound 11 in the NE (NE-
C) potentiated its in vitro antifungal activity, as shown by the
considerable decrease of the MIC values for dermatophytes
and yeast (Table 1). AmB is a classic example of an antifungal
agent that is associated with improved performance, including
the control of drug delivery, lower toxicity and improved
effectiveness, when it is administered in nanostructured
formulations.[24,25] In addition to the lipophilic nature of the NE,
high surface area due to reduced particle size improved drug
permeation across biological membranes, and resulted in
better drug efficiency, and bioavailability.[13,26]
With regards to in vivo testing, an alternative model of
fungal infection in embryonated chicken eggs was utilised.
Compound 11 reversed the infectious process by dermato-
phytic clinical strains in 100% of the analyzed eggs. For Candida
spp., the efficiency of compound 11 was 66.6%. Thus, in
addition to broad spectrum in vitro action, compound 11 was
also effective in vivo by greatly reducing the microbial load
associated with the infectious process, including for drug-
resistant species. It is important to emphasise that our study
represents, for the first time, an alternative model of fungal
infection in chicken eggs that has been applied for the
evaluation of antifungal activity of new small molecules.
Embryonic death in the treated eggs may be linked to infection
by Candida spp. or filamentous fungi strains, but there were
also eggs treated with compound 11 that resulted in dead
embryos. These results, and the deaths of the embryos in the
controls without inoculum, can be explained by manipulation
of the eggs, but may also be related to genetic defects or
embryonic development; the latter two factors are independ-
ent of the experimental procedure. The infection dose of 1 x
103 CFU mL  1 was considered low and was likely not the
determining factor for the embryo inviability.[27]
The Boyden chamber method (antichemotactic assay) was
used to evaluate whether compound 11 would inhibit poly-
morphonuclear neutrophil migration and to analyze the anti-
inflammatory properties of the compound. Leucocyte migra-
tion to the site of injury is considered one of the first major
steps for inflammation.[28] Our results suggested that com-
pound 11 acted in response to an acute inflammatory process
(Table 2). Mechanisms that promote inflammation and impair
the antifungal immune response are continually discovered. It
is known, for example, that C. albicans and Aspergillus fumigatus
colonizations are associated with elevated levels of pro-
inflammatory cytokines (IL-17, IL-23 and Th17).[11,29] Fungal
colonization, however, does not necessarily imply infection and
disease development. The stability of the host–fungus relation-
ship is maintained by a complex balance of pro- and anti-
inflammatory intracellular signals.[30,31] Consequently, control of
the inflammatory response may represent a strategy to combat
fungal infections.[11] Dermatophyte metabolites generally in-
duce inflammation at the site of infection.[32] Occasionally,
accentuated inflammatory responses are also associated with
increased severity and chronicity of mycoses.[31] Therefore, an
antifungal substance with related anti-inflammatory properties
will likely more effectively ameliorate a fungal infection.[33]
Compound 11 significantly reduced neutrophil migration (part
of the acute phase of inflammation) at 0.1 to 5 μg mL  1 (10
times lower than the MIC), and these results suggest that this
compound would work as a drug to treat fungal infections
associated with inflammatory disorders.
Sorbitol exerts osmotic protection on the fungal cell wall by
blocking chemicals from acting on this target,[34] and antifungal
activity will decrease in the presence of sorbitol if a drug acts
on the cell wall. Our results indicated that the antifungal effect
of compound 11 was not related to the cell wall, since the MIC
values did not vary with the addition of sorbitol.
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Some antifungal drugs act by interacting with ergosterol in
the cell membrane; ergosterol is an important target since it is
not present in mammalian cells. The addition of ergosterol in
growth medium will increase the concentration of this
substance outside of the membrane and allow the drug to
more easily interact with it. Consequently, if the drug’s
mechanism of action involves the cell membrane, it would
become less active (higher MICs).[35,36] Thus, MICs of the
compound 11 against all fungi strains were determined in the
presence of exogenous ergosterol. AmB, a commercial anti-
fungal, was used as control drug (Supporting Information,
Table S4). MICs of compound 11 increased after addition of
ergosterol to all Candida spp. and dermatophytes, and these
findings suggested a mechanism of action related to complex-
ation with ergosterol in the cell membrane, as similarly
observed for AmB. The loss of activity in the presence of
exogenous ergosterol was time- and dose-dependent for
Candida spp. (Supporting Information, Table S4). Since our
results indicated that compound 11 acts on the fungal cell
membrane, we next evaluated the effect of 11 on the fungal
cellular structure by SEM (Figure 1). C. albicans was treated with
either the antifungal ITZ or the compound 11. In both cases,
treated cells lost their internal contents in a process character-
istic of plasmolysis. This observation corroborated the pro-
posed mechanism of action of compound 11 against all
Candida spp. and dermatophytes strains presented in this
study.
Next, cytotoxicity studies demonstrated that the cell
damage was directly related to the concentration of compound
11. The mutagenic effect of 11 evaluated by the micronucleus
assay indicated that this compound does not generate
mutations at the concentration necessary for in vitro antifungal
activity (Figure 2). Besides, compound 11 did not cause
significant leucocyte death at the evaluated concentrations
(Figure 2). While 11 did not cause significant haemoloysis, we
observed a genotoxic effect at 50 μg mL  1.
Overall, a future topical formulation that contains the
chloro-substituted compound 11 would be safe. This supposi-
tion is corroborated by the lack of allergenicity by HET-CAM.
The HET-CAM, an alternative to the Draize test, mimics vascular
changes in the chorioallantoic membrane as a model for the
conjunctival ocular surface and can be a qualitative method of
assessing the potential irritancy of chemicals.[37] Besides that,
our results demonstrated that embryonated eggs are highly
susceptible to yeast and dermatophytes infection via the CAM
since these fungi proliferate radially on tissue and blood
vessels. The compound 11 was classified as nonirritant by the
HET-CAM assay . This result is a good indication of general low
membrane toxicity.
Conclusions
Fifteen allylic thiocyanates were screened against a panel of
Candida spp. and filamentous fungi. Six compounds exhibited
fungicide activity against Candida spp. at 50 μg mL  1. The 4-
chlorophenyl-substituted compound 11 demonstrated a fungi-
static effect (50 μg mL  1) against the entire fungal panel, and
exhibited anti-inflammatory capability by reducing neutrophil
migration. These results designate compound 11 as a possible
complement to conventional antifungal therapy with the
advantage of an anti-inflammatory effect, which can accelerate
the relief of symptoms, facilitate healing and prevent infection
dissemination. The incorporation of the compound 11 in a NE
greatly potentiated the in vitro antifungal activity as denoted
by reduced MIC values (MIC50=0.78 μg mL
  1 for dermatho-
phytes and 12.5 μg mL  1 for Candida spp.). In the in vivo assay,
compound 11 completely eliminated the dermatophytosis of
infected egg chorioallantoic membrane. The mechanism of
action of compound 11 was not related to the fungal cell wall
since MICs were not altered in the presence of sorbitol.
However, compound 11 formed an ergosterol complex similar
to that observed for AmB, and this complex is possibly related
to its broad-spectrum activity. SEM images suggested cell
damage through plasmolysis and modifications of the regular
yeast cell shape. Compound 11 also caused dose-dependent
DNA damage in human leucocytes. Micronucleus did not occur
after treatment with compound 11 at 25-50 μg mL  1, and this
finding indicated that the compound does not induce muta-
tions in human leucocytes at concentrations that produce
in vitro antifungal activity. In addition, 70% and 90% of
leucocytes became viable after treatment with compound 11
at 50 μg mL  1 and 25 μg mL  1, respectively; the compound did
not cause haemolysis. The results of HET-CAM classified this
compound as nonirritant. In addition to its antifungal, anti-
bacterial[14] and antituberculosis activities,[15] compound 11 can
be easily prepared from inexpensive and readily available
chemicals. NE that use compound 11 as the active component
can be a future alternative or a complement to conventional
treatments for cutaneous mycoses caused by yeast and
filamentous fungal pathogens.
Supporting Information Summary
Details of the experimental method can be found in the
electronic Supporting Information, as well as complementary
results such as complete tables of minimal inhibitory concen-
tration and figures that support the main results reported in
this article.
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SUPPORTING INFORMATION  1 
 2 
Experimental 3 
 4 
 5 
Chemical Synthesis 6 
Fifteen allylic thiocyanates 1–15 (Scheme 1) were readily synthesized from the corresponding allylic bromide 7 
16 (Scheme 1) according to previously described methods.[1–4] The typical procedure for the synthesis of allylic 8 
thiocyanates 1–15, consists of a stirred solution of allylic bromide 16 (1.0 mmol) in 4.0 mL of acetone/H2O (3:1 v/v) 9 
at 25 °C was added 2.0 mmol of NaSCN. After stirring for 1 h, the final mixture was diluted with CH2Cl2 and washed 10 
with H2O and brine. The organic extract was dried over Na2SO4, filtered and concentrated under reduced pressure. 11 
The resulting residue was purified by chromatography (hexane/ethyl acetate 9:1) to give the corresponding (Z)-2-12 
(thiocyanomethyl)alkenoates. Spectral and analytical data for the novel compound 2: 2 Methyl (Z)-3-(3-13 
nitrophenyl)-2-(thiocyanomethyl)-2-propenoate. Yield 98%; white solid, mp 71.0-72.0 °C. IR (KBr): max/cm-1 3085, 14 
2952, 2155, 1716, 1532, 1351, 1270. 1H NMR (400 MHz, CDCl3):  3.90 (s, 3H), 4.04 (s, 2H), 7.67 (t, J = 8.0 Hz, 15 
1H), 7.75-7.78 (m, 1H), 8.00 (s, 1H), 8.22-8.27 (m, 2H). 13C NMR (100 MHz, CDCl3):  30.8, 53.2, 111.7, 124.1, 16 
124.5, 129.1, 130.5, 135.0, 135.5, 141.9, 148.7, 165.8. Anal. Calcd for C12H10N2O4S (%): C, 51.79; H, 3.62; N, 17 
10.07. Found: C, 51.78; H, 3.55; N, 9.98. 18 
Each compound 1–15 was solved in DMSO and diluted using sterile ultrapure water to give solutions having 19 
DMSO in concentrations lower than 1% for subsequent investigation of antifungal/antichemotactic activities and 20 
toxicity determinations. 21 
 22 
Preparation and physicochemical characterization of nanoemulsion (NE) 23 
The NE were prepared in triplicate by the spontaneous emulsification solvent diffusion method, where an 24 
organic phase preheated to 40 °C, composed of the active compound 11 (NE-C, 5 mg), the oil (medium chain 25 
triglycerides – MCT, 0.15 g), the SPAN® 80 (0.077 g) and the solvent (ethanol, 27 mL), was injected under magnetic 26 
stirring into an aqueous phase (distilled water, 53 mL) containing Tween® 80 (0.077 g). The emulsion formed was 27 
kept under magnetic stirring for 10 min and then the organic solvent and part of the aqueous solvent were removed 28 
on a rotary evaporator to a final volume of 10 mL. For comparison purposes, a NE was prepared without the 29 
compound 11 (NE-WC).  30 
The NEs were submitted to a physicochemical characterization, where all the parameters were evaluated in 31 
triplicate. The pH of the NEs was determined directly on the samples by the use of a potentiometer. The NEs 32 
diameter and polydispersion index (PDI) evaluation was performed by photon correlation spectroscopy, after 33 
adequate dilution of an aliquot of the samples in ultrapure water (1:500) (Zetasizer Nanoseries, Malvern 34 
Instruments, UK). The zeta potential (ZP) values were determined by micro electrophoresis after dilution of the 35 
formulations into 10 mM NaCl solution. 36 
The compound 11 content in the formulations as well as the encapsulation efficiency was evaluated by high 37 
performance liquid chromatography (HPLC).  For this, an aliquot of the samples was diluted in 10 mL of methanol 38 
and subsequently sonicated for 10 min to compound extraction. After, samples were filtered through a 0.45 µm 39 
membrane and injected into the HPLC system. Chromatographic instruments and conditions were the following: 40 
LC-10A HPLC system (Shimadzu, Japan) equipped with a LC-20AT pump, an UV-VIS SPD-M20A detector, a 41 
CBM-20A system controller and a SIL-20A HT valve sample automatic injector. Separation was achieved at room 42 
temperature using an Inertsil ODS-3 C18 Gel Sciences column (150 mm × 4.6 mm, 5 μm) coupled with a C18 guard 43 
column. The isocratic mobile phase consisted of methanol and water (80:20, v/v) at 1.2 mL min-1 flow rate. The 44 
compound was detected at 284 nm with a retention time of about 4.03 min.  The analytical methodology was 45 
previously validated. The method was found to be linear (r = 0.995) at the concentration range of 2.5–12.5 µg mL-46 
1 and specific. 47 
The encapsulation efficiency was determined by ultrafiltration/centrifugation technique. An aliquot of the 48 
samples was placed in a 10.000 MW centrifugal device (Amicon®Ultra, Millipore) and free compound was 49 
2 
 
separated at 2200 × g for 10 min. The ultrafiltrate was analyzed by HPLC method. The encapsulation efficiency 50 
(%) was calculated from the difference between the total and free drug concentrations. The results of this analysis 51 
were expressed as averages followed by standard deviations (SD). 52 
 53 
In vitro antifungal susceptibility test 54 
 55 
Fungal strains 56 
Yeast species of the genus Candida (C. albicans - CA ATCC 18804, C. krusei - CK 02*, C. glabrata - CG 09*, 57 
and C. tropicalis - CT 72A*) and dermatophytic filamentous fungi (Microsporum canis - MCA 01, Microsporum 58 
gypseum - MGY 42, Trichophyton mentagrophytes - TME 16*, and Trichophyton rubrum - TRU 45) were selected 59 
for the screening of antifungal activity. Subsequently, for the comparison of the free compound and incorporated 60 
in the nanoformulation (NE-C), more yeasts and dermatophytes strains were included in this study. All fungal 61 
species are deposited in the Mycology Collection of the research group in Applied Mycology, Faculty of Pharmacy 62 
(Universidade Federal do Rio Grande do Sul, Brazil). For Candida spp. the resistance (*) was defined based on 63 
Kuriyama et al. (2005)[5] and CLSI breakpoints,[6,7] considering in this case the clinical isolates CK 02* resistant to: 64 
itraconazole (MIC = 1 µg mL-1) and fluconazole (MIC ≥ 64 µg mL-1), GC09* itraconazole (MIC > 4 µg mL-1) and 65 
miconazole (MIC = 8 µg mL-1), and CT 72A* resistant to itraconazole (MIC = 1 µg mL-1), miconazole (MIC > 8 µg 66 
mL-1), and voriconazole (MIC = 2 µg mL-1). As for dermatophytes, the resistance (in the sense of reduced 67 
susceptibility) was established according to the increase in minimal inhibitory concentration (MIC) values for some 68 
clinical strains in relation to the majority, considering the following resistance threshold concentrations: terbinafine 69 
- MIC ≥ 1 µg mL-1, griseofulvin - MIC ≥ 4 µg mL-1, and ketoconazole - MIC ≥ 8 µg mL-1. Consequently, the clinical 70 
isolate TME 16* was considered multidrug-resistant by the considerable elevation of MICs of three antifungal 71 
agents of different classes (MIC terbinafine = 4 µg mL-1, MIC griseofulvin > 32 µg mL-1 and MIC ketoconazole = 16 72 
µg mL-1).  73 
 74 
Antifungal agents 75 
Terbinafine (TBF), amphotericin B (AmB) and anidulafungin (AND), purity ≥ 97%, were supplied by Cristalia 76 
(Sao Paulo, Brazil), griseofulvin (GSF), purity ≥ 97%, was acquired from Wallace Pharmaceuticals (Mumbai, India), 77 
ketoconazole (KTZ), purity ≥ 96%, was obtained from All Chemistry (Sao Paulo, Brazil), fluconazole (FCZ) purity  78 
≥ 98% was obtained from Sigma-Aldrich (Sao Paulo, Brazil), itraconazole (ITZ) purity ≥ 97%, was supplied by 79 
Cassará laboratory (Dist. PHARMOS; Buenos Aires, Argentina), miconazole (MCZ) purity ≥ 97%, was supplied by 80 
Valdequimica Chemical Products (Sao Paulo, Brazil), and voriconazole (VRZ); purity ≥ 98%, was supplied by Pfizer 81 
(Sao Paulo, Brazil). The preparation of stock and work solutions followed the recommendations of the CLSI.[8] The 82 
commercial antifungals were used as reference substances for comparison with the synthetic compounds in the 83 
tests conducted. 84 
 85 
Determination of MIC and minimal fungicidal concentration (MFC) 86 
The series of synthetic compounds and the NE containing the compound 11 were evaluated for MIC 87 
determination, through the broth microdilution technique.[6–8] The inocula of yeasts (0.5x103 to 2.5x103 CFU mL-1) 88 
and dermatophytes (1.0x103 to 3.0x103 CFU mL-1) were prepared from cultures grown on sabouraud dextrose agar 89 
(SDA; Kasvi, Brazil) and potato dextrose agar (PDA; Neogen, USA), respectively. [6–8] Posteriorly, aliquots of each 90 
serial microdilution (corresponding to MIC, 2xMIC, and 4xMIC) were spread on SDA (Candida) and PDA 91 
(dermatophytes), incubated at 35 °C,[6–8]  and analyzed to determine the MFC, which was defined as the lowest 92 
concentration that yielded up to three colonies.[9]  93 
 94 
In vivo antifungal efficacy in Infected Egg Test-Chorioallantoic Membrane (IET-CAM)  95 
3 
 
Fresh and fertile white eggs were kept under optimized incubation conditions (3839 °C, 5560% humidity, 12 96 
days). On the 4th day, the CAM of eggs were infected with 0.1 mL inoculum 4x/day until the occurrence of the 97 
infectious process was confirmed by the visualization of colonies onto the CAM. The preparation of the yeast (4x103 98 
CFU mL-1) and filamentous fungi (1.0x103 CFU mL-1) inocula followed the CLSI.[6–8]  On the 8th day of incubation, 99 
the treatment was started. An aliquot of 0.1 mL of compound 11 (200 µg mL-1, 0.5% DMSO solution) and the 100 
negative control (0.9% NaCl) was added onto the CAM. On the 12th day, eggs were reopened. 0.1 mL of the 101 
embryonic contents were removed, spread on sabouraud agar plates, incubated and the viability of the embryo 102 
verified.[10] Subsequently, counting of colony forming units was performed.[10] The study was submitted and 103 
approved by the Committee on Ethics in the Use of Animals (CEUA nº 4/2016 - Instituto Federal Catarinense, 104 
Concordia, Brazil). The experiment was carried out in triplicate. 105 
 106 
Antichemotactic assay 107 
The evaluation of antichemotactic activity was performed according to the method of the modified Boyden 108 
chamber as described by Suyenaga et al. (2011).[11] Prior to assay, neutrophils were treated with the compound 109 
11 dissolved in Hank’s balanced salt solution (HBSS, pH 7.4) in concentrations of 0.001 to 10 μg mL-1, at 37 °C 110 
for 30 min. As negative control was used a neutrophils solution with no addition of antichemotactic agent. 111 
Indomethacin was used as positive control. The protocol was approved by the Committee on the Ethics of Animal 112 
Experiments of the Federal University of Rio Grande do Sul (Permission no. 32226, approved on April 24, 2017). 113 
 114 
Investigation of antifungal mechanism of action 115 
 116 
Sorbitol assay 117 
The sorbitol solution (0.8 M, Sigma-Aldrich) was prepared and diluted in the culture medium (RPMI 1640; 118 
Sigma-Aldrich). Then, microplates were incubated at 35 °C for 168 h. The MIC was visually determined in the 119 
assay to compound 11, in the presence and absence of sorbitol.[12] The minimal effective concentration (MEC), 120 
which is the lowest concentration of antifungal agent that leads to the growth of small, round and compact hyphal 121 
forms, was determined in triplicate only for the antifungal AND (drug control).[6–8] 122 
 123 
Ergosterol assay 124 
The susceptibility test was performed in triplicate according to the CLSI[6–8], in the presence and absence of the 125 
exogenous ergosterol[13] (Sigma-Aldrich), with compound 11 and using amphotericin B (AmB) as drug control.[13] 126 
The microplates were incubated (35 °C, 168 h) and MICs were determined visually in the presence and absence 127 
of exogenous ergosterol, in different concentrations and times.[13] 128 
 129 
Scanning electron microscopy (SEM) analysis 130 
After the incubation period defined by the susceptibility test, wells containing the coverslips were washed three 131 
times with phosphate-buffered saline (PBS). After washing, adhered cells received 500 μL of glutaraldehyde (2.5%, 132 
type 1, Sigma-Aldrich), diluted with sodium cacodylate (0.1 mol L-1, pH 7.2, Sigma-Aldrich), and kept for 1 h at 133 
room temperature. Then, the wells were washed three times with sodium cacodylate (0.1 mol L-1, pH 7.2) 134 
containing sucrose (0.2 mol L-1) and MgCl2 (2 mmol L-1). Adhered cells were dehydrated in a series of freshly 135 
prepared solutions of ethanol (30, 50, and 70%, for 5 min/step, 95% and 2x100%, for 10 min/step). Samples were 136 
subjected to critical point drying (EM CPD 300, Leica), mounted on metallic stubs, sputter-coated with a 15–20 nm 137 
gold-palladium layer, and visualized in a scanning electron microscope (Carl Zeiss EVO® MA10, Germany) 138 
operating at 10 kV. The images were performed with a strain of C. albicans (CA ATCC 18804) without treatment 139 
(control) and treated with compound 11 (25 µg mL-1 - subinhibitory concentration) and ITZ (1 µg mL-1, drug control). 140 
 141 
Toxicity evaluation 142 
 143 
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Cell culture, cytotoxicity, genotoxicity and mutagenicity 144 
Cell cultures of human leukocytes were prepared using venous blood collected by venipuncture from a male 145 
volunteer (protocol #23.081.005770/009-38). Aliquots (1 mL) of whole blood were immediately transferred to 10 146 
mL of RPMI 1640 medium supplemented with 1% phytohemagglutinin, 10% fetal bovine serum and 1% 147 
streptomycin/penicillin.[14] Subsequently, cell culture treatments were performed with compound 11 (25 µg mL-1 148 
and 50 µg mL-1, in 0.5% DMSO), hydrogen peroxide solution (H2O2, 100 μmol L-1, positive control), and PBS 149 
(negative control). Cell cultures were incubated (CO2 incubator for cell culture, 5% CO2, Model MCO-19AIC, 150 
Sanyo) at 37 °C for 72 h.[15] Cytotoxic, genotoxic, and mutagenic parameters were established, in triplicate. Cell 151 
viability was assessed with 0.2% trypan blue (Sigma-Aldrich), according to Burow et al. (1998).[15] Genotoxicity 152 
was performed by the comet assay. Cells were classified according varying from 0 (no visible damage) to 4 153 
(maximum damage) to provide a unique damage index (ID) from 0 to 400.[16] The assessment of mutagenicity was 154 
carried out by Panótico Rápido® (Laborclin), wherein all particles within the cells separated from the nucleus are 155 
accounted for as micronuclei (MN).[14,17] 156 
 157 
Hemolysis assay 158 
The hemolysis assay was performed using rabbit blood. After collection, the blood was mixed with the 159 
anticoagulant K2-EDTA. Rabbit erythrocytes were harvested by centrifugation for 5 min at 400 rpm and washed 160 
three times in PBS. A suspension of the 1% erythrocytes was prepared in PBS. The compound 11 solution was 161 
prepared and incubated with the erythrocyte suspension for 15 min h at 37°C. After incubation, the cells were spun 162 
down by centrifugation, the supernatant was transferred to a 96-well plate and the absorbance (650 nm) measured 163 
using a microplate spectrophotometer (BioTek Instruments). Two controls were used in this assay: (i) PBS was 164 
used as a negative control (0% hemolysis), and (ii) water was used as positive control (100% hemolysis). 165 
 166 
Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) 167 
Fresh and fertile white eggs (Lohmann selected Leghorn, LSL) were kept under optimized incubation conditions 168 
(3839 °C, 5560% humidity, 10 days). On the 10th day, the eggshell, around the airspace, was removed with a 169 
rotary tool (Dremel, WI). Subsequently, 0.3 mL of compound 11 (200 µg mL-1, 0.5% DMSO solution) and controls 170 
(negative control: 0.9% NaCl; positive control: 0.1 mol L-1 NaOH) were added to the CAM of the eggs.[18] The irritant 171 
effect was observed at three times: 30 sec, 2 min and 5 min after application of compound 11 and controls. The 172 
result of the irritation score (IS) was calculated according to the [Eq. (1)][18] and presents a maximum value of 21. 173 
The eggs were analyzed in relation to the appearance of hemorrhaging, lysis, and coagulation. Classification 174 
criterion used: 0 to 4.9 nonirritant (or practically no irritation); 5.0 to 21 irritant (moderate to severe or extreme 175 
irritation). [18] The assay was performed in triplicate.  176 
 177 
Equation 1. Formula for determination of irritation score (IS) 178 
IS = ((
(301 − hemorrhage time )
300
) x5) + ((
(301 − lysis time)
300
) x7) + ((
(301 − coagulation time)
300
) x9) 179 
 180 
 181 
Statistical analysis  182 
Differences between the control and treatments were statistically analyzed by ANOVA followed by Tukey’s test 183 
(p <0.05 was considered statistically significant). Data analysis was performed using the GraphPad Prism 5.0 184 
software and expressed as mean ± SD. 185 
 186 
 187 
 188 
 189 
Results 190 
 191 
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Table S1. MIC/MFCs (µg mL-1) for allylic thiocyanates 1–15. 194 
Table S2. Number of eggs with and without fungal growth and number of eggs with live and dead embryos after 195 
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(B) Control, without treatment. 204 
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Table S1. MIC/MFCs (µg mL-1) for allylic thiocyanates 1–15. 241 
Compounds 
and antifungal 
drugs 
Dermatophytes Candida spp. 
MCA 01 MGY 42 TME 16* TRU 45 CA ATCC 18804 CK 02* CG 09* CT 72A* 
1 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
2 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 50/50 50/50 50/50 50/50 
3 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 50/50 50/50 50/50 50/50 
4 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
5 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 50/50 50/50 50/50 50/50 
6 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
7 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
8 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 50/50 50/50 50/50 50/50 
9 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 50/50 50/50 50/50 50/50 
10 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
11 50/>200 50/>200 50/>200 50/>200 50/>200 50/>200 50/>200 50/>200 
12 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
13 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
14 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 50/50 50/50 50/50 50/50 
15 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 ˃50/>50 
TBF 0.03 (S) 0.03 (S) 4 (R*) 0.06 (S) - - - - 
GSF 1 (S) 1 (S) >32 (R*) 1 (S) -  - - - 
KTZ 0.5 (S) 1 (S) 16 (R*) 1 (S) 0.25 (S) 1 (S) 0.5 (S) 1 (S) 
FCZ - - - - 1 (S) ≥ 64 (R) 0.25 (DDS) 2 (S) 
ITZ - - - - - 1 (R) >4 (R) 1 (R) 
MCZ - - - - - 0.5 (S) >8 (R) >8 (R) 
VRZ - -  - - - - - 2 (R) 
 242 
*Multidrug-resistant and resistant fungal isolates; MIC, minimal inhibitory concentration; MFC, minimal fungicidal 243 
concentration; MCA, Microsporum canis; MGY, Microsporum gypseum; TME, Trichophyton mentagrophytes; TRU, 244 
Trichophyton rubrum; CA, Candida albicans; CK, Candida krusei; CG, Candida glabrata; CT, Candida tropicalis. 245 
TBF, terbinafine; GSF, griseofulvin; KTZ, ketoconazole; FCZ, fluconazole; ITZ, itraconazole; MCZ, miconazole; 246 
VRZ, voriconazole; R, resistance; R*, resistance in the sense of reduced susceptibility compared to other strains; 247 
S, susceptible; IR, intermediary resistance; DDS, dose-dependent susceptibility.[6–8,19] 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
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Table S2. Number of eggs with and without fungal growth and number of eggs with live and dead embryos after treatment with compound 11 and controls. 
 
 
Fungi 
Compound 11  
Efficiency 
(%) 
Control 1 Control 2 Control 3 
Eggs Embryos Eggs Embryos Eggs Embryos Eggs Embryos 
With 
microbial 
growth 
Without 
microbial 
growth 
Deads Lives With 
microbial 
growth 
Without 
microbial 
growth 
Deads Lives With 
microbial 
growth 
Without 
microbial 
growth 
Deads Lives With 
microbial 
growth 
Without 
microbial 
growth 
Deads Lives 
MCA 01 0 3 0 3 100 3 0 3 0 2 1 2 1 1 2 1 2 
MGY 42 0 3 0 3 100 3 0 3 0 3 0 3 0 2 1 2 1 
TME 16* 0 3 0 3 100 3 0 3 0 3 0 3 0 1 2 1 2 
TRU 45 0 3 0 3 100 3 0 3 0 3 0 1 2 3 0 3 0 
CA ATCC 
18804 
1 2 1 2 66.6 3 0 2 1 1 2 0 3 0 3 0 3 
CK 02* 1 2 1 2 66.6 3 0 2 1 1 2 0 3 0 3 0 3 
CG 09* 1 2 1 2 66.6 3 0 3 0 3 0 1 2 2 1 0 3 
CT 72A* 1 2 1 2 66.6 3 0 2 1 3 0 1 2 1 2 0 3 
 
*Multidrug-resistant and resistant fungal isolates; MCA, Microsporum canis; MGY, Microsporum gypseum; TME, Trichophyton mentagrophytes; TRU, Trichophyton rubrum; CA, Candida 
albicans; CK, Candida krusei; CG, Candida glabrata; CT, Candida tropicalis. Control 1 consists of chorioallantoic membrane of egg inoculated with the clinical strains; Control 2 normal 
eggs without inoculation and without treatment; and Control 3 normal eggs without inoculation and with compound 11. 
 
8 
 
 
 
Figure S1. Macroscopic changes in infected embryonated eggs; (A) Treatment with compound 11 (200 µg mL-1) 
(B) Control, without treatment. 
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Table S3. MICs (µg mL-1) for the compound 11 and MECs (µg mL-1) for AND, in the presence and absence of 
sorbitol. 
           Time                               48 h 96 h 168 h 
Dermatophytes 
and Candida spp. 
Compound 
11 
AND Compound 
11 
AND Compound  
11 
AND 
AS PS AS PS AS PS AS PS AS PS AS PS 
MCA 01 - - - - 50 50 32 128 >800 >800 64 >256 
MGY 42 - - - - 50 50 32 128 >800 >800 64 >256 
TME 16* - - - - 50 50 32 128 >800 >800 64 >256 
TRU 45 - - - - 50 50 32 128 >800 >800 64 >256 
CA ATCC 18804 50 50 0.12 32 100 100 0.12 ˃64 >800 >800 0.12 >64 
CK 02* 50 50 0.12 32 100 100 0.12 ˃64 >800 >800 0.12 >64 
CG 09* 50 50 0.12 32 100 100 0.12 ˃64 >800 >800 0.12 >64 
CT 72A* 50 50 0.12 32 100 100 0.12 ˃64 >800 >800 0.12 >64 
 
*Multidrug-resistant and resistant fungal isolates. Abbreviations: MIC, minimal inhibitory concentration; MEC, 
minimal effective concentration; AND, anidulafungin; AS, absence of sorbitol; PS, presence of sorbitol; MCA, 
Microsporum canis; MGY, Microsporum gypseum; TME, Trichophyton mentagrophytes; TRU, Trichophyton 
rubrum; CA, Candida albicans; CK, Candida krusei; CG, Candida glabrata; CT, Candida tropicalis. 
 
 
Table S4. MICs (µg mL-1) for the compound 11 and AmB, in the presence and absence of ergosterol. 
Fungi strains                       Reading 1 (µg mL-1) Reading 2 (µg mL-1) 
Compound 11 MIC1 MIC 2 MIC 3 MIC 4 MIC 5 MIC 1 MIC 2 MIC 3 MIC 4 MIC 5 
MCA 01 50 50 50 50 50 50 50 50 50 100 
MGY 42 50 50 50 50 50 50 50 50 50 100 
TME 16* 50 50 50 50 50 50 50 50 50 100 
TRU 45 50 50 50 50 50 50 50 50 50 100 
CA ATCC 18804 50 50 100 100 200 50 100 100 100 200 
CK 02* 50 50 50 100 100 50 50 100 200 200 
CG 09* 50 50 50 200 200 50 50 100 400 400 
CT 72A* 50 50 100 200 400 50 100 100 400 400 
AmB MIC 1 MIC 2 MIC 3 MIC 4 MIC 5 MIC 1 MIC 2 MIC 3 MIC 4 MIC 5 
MCA 01 0.5 2 4 4 8 0.5 2 4 4 8 
MGY 42 4 4 4 8 16 4 4 4 8 16 
TME 16* 2 8 8 8 16 2 8 16 16 32 
TRU 45 2 2 4 4 8 2 8 16 16 32 
CA ATCC 18804 1 2 4 16 16 1 2 16 128 128 
CK 02* 1 2 4 16 16 1 2 128 128 128 
CG 09* 2 2 4 8 16 2 2 128 128 128 
CT 72A* 0.5 2 4 32 128 0.5 2 ˃128 ˃ 128 ˃ 128 
 
*Multidrug-resistant and resistant fungal isolates. AmB = Amphotericin B; CA = C. albicans (CA ATCC 18804); CT 
= C. tropicalis (CT 72A*); CK= C. krusei (CK 02); CG= C. glabrata (CG 09); MCA= M. canis (MCA 01); MGY= M. 
gypseum (MGY 42); TME = T. mentagrophytes (TME 16*); TRU= T. rubrum (TRU 50). MIC1 corresponds to MIC 
without addition of commercial ergosterol; MIC2, MIC3, MIC4, and MIC5, correspond to MIC with addition of 
ergosterol at the concentration of 50 µg mL-1, 100 µg mL-1, 150 µg mL-1, and 200 µg mL-1, respectively. For Candida 
spp., readings 1 and 2 were performed after 2 and 5 days of incubation, respectively; for dermatophytes, readings 
1 and 2 were performed after 4 and 7 days of incubation, respectively. 
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